(R)-Oxiracetam - CAS 68252-28-8
Catalog number: 68252-28-8
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C6H10N2O3
Molecular Weight:
158.16
COA:
Inquire
Targets:
Others
Description:
(R)-Oxiracetam is the (R)-enantiomer of the nootropic drug oxiracetam, which is a nootropic drug of the racetam family and stimulant. It is safe even when high doses are consumed for a long period of time, but it is not approved by Food and Drug Administration for any medical use in the United States.
Purity:
>98%
Synonyms:
(R)-(+)-Oxiracetam; (R)-ISF 2522; (R)-ISF2522;
MSDS:
Inquire
InChIKey:
IHLAQQPQKRMGSS-SCSAIBSYSA-N
InChI:
InChI=1S/C6H10N2O3/c7-5(10)3-8-2-4(9)1-6(8)11/h4,9H,1-3H2,(H2,7,10)/t4-/m1/s1
Canonical SMILES:
C1C(CN(C1=O)CC(=O)N)O
1.Rapid quantitative analysis of oxiracetam in human plasma by liquid chromatography/electrospray tandem mass spectrometry.
Son J1, Lee J, Lee M, Lee E, Lee JH, La S, Kim DH. J Pharm Biomed Anal. 2004 Nov 15;36(3):657-61.
A rapid and accurate reversed-phase liquid chromatography-tandem mass spectrometry (LC-MS/MS) method has been developed and validated for the quantitative determination of oxiracetam in human plasma. Oxiracetam, a highly polar compound, was successfully retained by Atlantis dC18 reversed-phase column and detected with triple-quadrupole tandem mass spectrometry. After addition of internal standard (piracetam) to human plasma, plasma was simply precipitated with two volume of acetonitrile, evaporated and dissolved in 0.1% acetic acid. This method for the determination of oxiracetam was accurate and reproducible, with a limit of quantitation of 0.2microg/ml in human plasma. The standard calibration curve for oxiracetam was linear (r(2) = 0.999) over the concentration range 0.2-40.0microg/ml in human plasma. The intra- and inter-day precision over the concentration range of oxiracetam was lower than 8.3% (relative standard deviation, %R.S.D.
2.Calcium entry blockers and oxiracetam have opposite effects on the density of dihydropyridine receptors in rat cerebral cortex.
Dudkin SM1, Polev PV, Soldatov NM. Brain Res. 1990 Aug 20;525(2):319-21.
Ca2+ entry blockers riodipine, D-cis-diltiazem and verapamil, when administered i.p. to rats at a dose of 10 mg/kg, produced two-fold decreases in the density of 1,4-dihydropyridine (DHP) receptors in rat cerebral cortex, as revealed by Scatchard plot analysis of radioligand binding made 24 h after the first injection. Thereafter, the number of DHP binding sites increased up to the initial level on day 4 of the treatment. The nootropic drug oxiracetam, when injected simultaneously with Ca2+ channel blockers at a dose of 10 mg/kg, prevented this transient decrease in DHP receptor density in brain. These results can explain the opposite modulation of memory retention by calcium antagonists and nootropic drugs that has been observed previously.
3.Effects of nootropic drugs in a scopolamine-induced amnesia model in mice.
Verloes R1, Scotto AM, Gobert J, Wülfert E. Psychopharmacology (Berl). 1988;95(2):226-30.
Scopolamine (3 mg/kg IP) given before an acquisition trial, reduced the retention of a one-trial passive avoidance "step through" response in mice. A single administration of cholinergic agonists such as oxotremorine, BM-5, or arecoline, antagonized this amnesic effect of scopolamine. A significant anti-amnesic effect was also found with nootropic drugs such as piracetam and ucb L059, whereas ucb L060 (the enantiomer of ucb L059), oxiracetam and rolziracetam were shown to be ineffective. Moreover, ucb L059, administered twice daily for 3 days, counteracted the amnesic effects of scopolamine completely, whereas ucb L060 was again inactive. The results demonstrate that: (a) this model of impaired cognition by scopolamine is able to discriminate between closely related chemical substances and even stereoisomers; and (b) nootropic drugs, such as ucb L059, are more effective after repeated rather than after acute administration.
4.Glycosides of cistanche improve learning and memory in the rat model of vascular dementia.
Chen J1, Zhou SN, Zhang YM, Feng YL, Wang S. Eur Rev Med Pharmacol Sci. 2015 Apr;19(7):1234-40.
OBJECTIVE: Glycosides of cistanche (GC) is extracted from Xin Jiang Cistanche, which is widely used as a Chinese herb. This study aims to evaluate the effects of GC on vascular dementia (VD).
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Products


CAS 1704801-24-0 AX-024 hydrochloride

AX-024 hydrochloride
(CAS: 1704801-24-0)

AX-024 hydrochloride is an inhibitor of T cell receptor (TCR) that selectively inhibits the TCR-Nck interaction. By modulating TCR signaling, AX-024 prevents th...

CAS 156436-90-7 Motexafin Lutetium Hydrate

Motexafin Lutetium Hydrate
(CAS: 156436-90-7)

The hydrate form of Motexafin Lutetium that has been found to probably be effective in antineoplastic antiatheroscleroticand studies.

CAS 1197-18-8 Tranexamic Acid

Tranexamic Acid
(CAS: 1197-18-8)

Tranexamic Acid is an antifibrinolytic for blocking lysine-binding sites of plasmin and elastase-derived plasminogen fragments with IC50 of 5 mM.

CGP 20376
(CAS: 81059-04-3)

CGP 20376 is a benzothiazole compound and it has antifilarial properties.

CAS 312946-37-5 LDN-27219

LDN-27219
(CAS: 312946-37-5)

LDN-27219 is a revesible inhibitor of transglutaminase 2 (TG2) that binds to the GTP binidng site of the enzyme and inhbits activity with and IC50 of 600 nM.

CAS 1951408-58-4 MAK683

MAK683
(CAS: 1951408-58-4)

MAK683 is an inhibitor of embryonic ectoderm development protein (EED) with potential antineoplastic activity. MAK683 binds to the domain of EED that interacts ...

CAS 140111-52-0 (±)-Epibatidine

(±)-Epibatidine
(CAS: 140111-52-0)

(±)-Epibatidine is a potent nicotinic agonist (Ki = 0.02 and 233 nM for α4β2 and α7 nicotinic receptors, respectively).

CAS 481-46-9 Ginkgetin

Ginkgetin
(CAS: 481-46-9)

Ginkgetin is a natural biflavonoid isolated from leaves of Ginkgo biloba L. According to reports, it has anti-inflammatory and anti-cancer effects.

Chemical Structure

CAS 68252-28-8 (R)-Oxiracetam

Quick Inquiry

Verification code

Featured Items